Načítá se...
Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
Urothelial carcinoma is one of the most common cancers in the United States, yet outcomes are historically suboptimal. Since 2016, the approval of five programmed cell death 1 and programmed death-ligand 1 immune checkpoint inhibitors for locally advanced and metastatic urothelial carcinoma has led...
Uloženo v:
| Vydáno v: | J Cancer Immunol (Wilmington) |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8276975/ https://ncbi.nlm.nih.gov/pubmed/34263255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.33696/cancerimmunol.3.047 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|